ERCC6 and acute myeloid leukemia: The synergistic sensitivity observed in a panel of acute myeloid leukemia (AML) cells exposed to olaparib and 5-azadC has been ascribed to a failure to repair the 5-azadC-induced lesions through BER [137], which could also be a mechanism behind the sensitivity of CSB-deficient cells to this drug since CSB also plays a role in BER.